Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fundamental aspects of DMPK optimization of targeted protein degraders
Carina Cantrill, Prasoon Chaturvedi, Caroline Rynn, et al.
Drug Discovery Today (2020) Vol. 25, Iss. 6, pp. 969-982
Closed Access | Times Cited: 117

Showing 26-50 of 117 citing articles:

Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton’s Tyrosine Kinase for the Treatment of Lymphoma
Jingyu Zhang, Jinxin Che, Xiaomin Luo, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 9096-9125
Closed Access | Times Cited: 39
Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design
Johannes Krieger, F.J. Sorrell, Ansgar Wegener, et al.
ChemMedChem (2023) Vol. 18, Iss. 8
Closed Access | Times Cited: 35
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 32
Small-Molecule Hydrophobic Tagging: A Promising Strategy of Druglike Technology for Targeted Protein Degradation
Shaowen Xie, Jingjie Zhu, Junda Li, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 10917-10933
Closed Access | Times Cited: 29
Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders
Laurie P. Volak, Heide Marika Duevel, Sara C. Humphreys, et al.
Drug Metabolism and Disposition (2023) Vol. 51, Iss. 7, pp. 792-803
Closed Access | Times Cited: 27
The rise of degrader drugs
Mingxing Teng, Nathanael S. Gray
Cell chemical biology (2023) Vol. 30, Iss. 8, pp. 864-878
Open Access | Times Cited: 25
Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
Barmak Mostofian, Holli‐Joi Martin, Asghar M. Razavi, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 17, pp. 5408-5432
Open Access | Times Cited: 19
Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives
Jiahao Li, Gong Chen, Haiting Zhou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5489-5489
Open Access | Times Cited: 10
Current status and future directions of high-throughput ADME screening in drug discovery
Wilson Z. Shou
Journal of Pharmaceutical Analysis (2020) Vol. 10, Iss. 3, pp. 201-208
Open Access | Times Cited: 65
Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo
Guoshun Luo, Zhenbang Li, Xin Lin, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 11, Iss. 5, pp. 1300-1314
Open Access | Times Cited: 58
Systematic Investigation of the Permeability of Androgen Receptor PROTACs
Duncan E. Scott, Timothy P. C. Rooney, Elliott D. Bayle, et al.
ACS Medicinal Chemistry Letters (2020) Vol. 11, Iss. 8, pp. 1539-1547
Open Access | Times Cited: 52
Bispecific Estrogen Receptor α Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening
Jeremy S. Disch, Jennifer M. Duffy, Esther C. Y. Lee, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 8, pp. 5049-5066
Closed Access | Times Cited: 49
Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)
Shaowen Xie, Yuan Sun, Yulin Liu, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 9120-9140
Closed Access | Times Cited: 45
Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities
Pritam Maity, Joydeep Chatterjee, Kiran T. Patil, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3135-3172
Closed Access | Times Cited: 18
A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs)
Robin Thomas Ulrich Haid, Andreas Reichel
Pharmaceutics (2023) Vol. 15, Iss. 1, pp. 195-195
Open Access | Times Cited: 14
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs
Rohan Kalyan Rej, Srinivasa Rao Allu, Joyeeta Roy, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 494-494
Open Access | Times Cited: 5
Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
Sandra Kuemper, Andrew G. Cairns, Kristian Birchall, et al.
Frontiers in Molecular Neuroscience (2024) Vol. 17
Open Access | Times Cited: 4
Accelerating PROTACs Discovery Through a Direct‐to‐Biology Platform Enabled by Modular Photoclick Chemistry
Ke‐Nian Yan, Yong‐Qiang Nie, Jiayu Wang, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Open Access | Times Cited: 4
Development and validation of LC-MS/MS methods for the pharmacokinetic assessment of the PROTACs bavdeglutamide (ARV-110) and vepdegestrant (ARV-471)
Janis Niessen, Jenny M. Nilsson, Karsten Peters, et al.
Journal of Pharmaceutical and Biomedical Analysis (2024) Vol. 249, pp. 116348-116348
Open Access | Times Cited: 4
PROTAC Cell Permeability and Oral Bioavailability: A Journey Into Uncharted Territory
Vasanthanathan Poongavanam, Jan Kihlberg
Future Medicinal Chemistry (2021) Vol. 14, Iss. 3, pp. 123-126
Closed Access | Times Cited: 38
PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs
Marı́a Maneiro, Elena De Vita, Daniel Conole, et al.
Progress in medicinal chemistry (2021), pp. 67-190
Closed Access | Times Cited: 34
Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
Sinan Ma, Jianai Ji, Yuanyuan Tong, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 7, pp. 2990-3005
Open Access | Times Cited: 23
Natural product-based PROteolysis TArgeting Chimeras (PROTACs)
Miaomiao Liu, Alexander P. Martyn, Ronald J. Quinn
Natural Product Reports (2022) Vol. 39, Iss. 12, pp. 2292-2307
Closed Access | Times Cited: 22
Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma
Muhammad Rishfi, Simon Krols, Fien Martens, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115033-115033
Open Access | Times Cited: 21
Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer
Jiayi Lin, Haijun Liu, Ye Wu, et al.
Small (2023) Vol. 19, Iss. 18
Closed Access | Times Cited: 13

Scroll to top